Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Other Non Operating Income: 2016-2025

Historic Other Non Operating Income for Heron Therapeutics (HRTX) over the last 10 years, with Sep 2025 value amounting to -$11.3 million.

  • Heron Therapeutics' Other Non Operating Income fell 2807.44% to -$11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.6 million, marking a year-over-year decrease of 555.77%. This contributed to the annual value of $430,000 for FY2024, which is 23.21% down from last year.
  • Latest data reveals that Heron Therapeutics reported Other Non Operating Income of -$11.3 million as of Q3 2025, which was down 1,424.06% from -$744,000 recorded in Q2 2025.
  • Heron Therapeutics' 5-year Other Non Operating Income high stood at $2.0 million for Q4 2024, and its period low was -$11.3 million during Q3 2025.
  • Its 3-year average for Other Non Operating Income is -$1.2 million, with a median of -$234,500 in 2023.
  • Per our database at Business Quant, Heron Therapeutics' Other Non Operating Income surged by 455.25% in 2024 and then crashed by 2,807.44% in 2025.
  • Over the past 5 years, Heron Therapeutics' Other Non Operating Income (Quarterly) stood at $868,000 in 2021, then skyrocketed by 52.30% to $1.3 million in 2022, then plummeted by 203.85% to -$79,000 in 2023, then tumbled by 393.67% to $2.0 million in 2024, then slumped by 2,807.44% to -$11.3 million in 2025.
  • Its Other Non Operating Income was -$11.3 million in Q3 2025, compared to -$744,000 in Q2 2025 and -$519,000 in Q1 2025.